Alpha-GPC

Overview

Alpha-GPC is the choline supplement with the best pharmacokinetics and the weakest relevance. Those two facts are usually presented as one.

It is genuinely well absorbed, it genuinely crosses the blood-brain barrier, and it genuinely raises the availability of choline for acetylcholine synthesis. Most supplements fail somewhere in that chain. This one does not.

The failure is one step later, and it is a failure of evidence rather than of chemistry.

Mechanism of Action

Acetylcholine is the neurotransmitter of attention, learning and neuromuscular signalling. It is built from choline and acetyl-CoA, and choline is the part the diet supplies — mostly from eggs, liver and meat.

Alpha-GPC is choline attached to a glycerophosphate backbone. That structure survives absorption intact, crosses into the brain, and is then cleaved to release choline directly where it is used. Choline bitartrate, the cheap alternative, raises blood choline but penetrates the brain poorly and feeds gut bacteria on the way. Citicoline is the closest comparison and behaves similarly.

By weight alpha-GPC is roughly 40% choline. So 600 mg supplies about 240 mg of choline — meaningful against a daily adequate intake of 425 to 550 mg, and less than two eggs.

That last comparison is worth keeping in mind for the rest of this page.

What It Actually Delivers

• In dementia and post-stroke recovery: modest but reproducible improvements on cognitive scales, at 1200 mg daily over months
• In healthy adults, cognition: almost nothing has been measured properly; the studies that exist are small, short and inconsistent
• Power output: two small trials found improvements in isometric strength and bench throw force; another found nothing for vertical jump. Sample sizes of seven to fifteen
• Subjective focus: commonly reported, unmeasured, and the effect most people are actually buying
• Growth hormone: a transient rise after a single dose, with no demonstrated downstream consequence

The Gap Between the Studies and the Product

This is the part the category needs stated plainly.

The impressive citations behind alpha-GPC are Italian trials from the 1990s and 2000s in Alzheimer's disease, vascular dementia and acute stroke, running at 1200 mg daily for three to twelve months, sometimes starting with injections. Several were open-label. They are not bad studies, and their result is real within their population.

But that population is defined by a degenerating cholinergic system. Alzheimer's drugs work by preserving acetylcholine, because that is the deficit. Giving more raw material to a system that is short of it is a coherent intervention. Giving more to a system that is not short of it has no reason to do anything, and this is the same wall that carnitine hits with fat oxidation: a mechanism only pays out where it is the bottleneck.

Then the dose collapses on the way to the shelf. The trials used 1200 mg daily for months. A pre-workout contains 150 to 300 mg, and often that figure is the blend rather than the compound, halving it again. Nobody has tested 150 mg once, in a healthy adult, against a placebo, at the scale required to detect a small effect.

So the honest summary: a well-designed delivery vehicle for a substrate that healthy, well-fed people are rarely short of, sold on the strength of studies in people who were.

The TMAO Question, Specifically Here

Choline is metabolised by gut bacteria into trimethylamine, which the liver converts to TMAO. Observational research associates TMAO with atherosclerosis, and the causal question is unsettled. Carnitine carries the same issue.

Alpha-GPC adds a second, more uncomfortable finding: a large Taiwanese insurance-database analysis reported a dose-dependent association between alpha-GPC prescriptions and ten-year stroke incidence. The obvious objection is the right one — this is a drug prescribed to people with cognitive decline and vascular disease, so confounding by indication is almost certainly doing most of the work. It is not evidence of harm.

It is a reason not to take a large dose indefinitely for an effect that was never demonstrated in you. That calculation looks different for someone whose ApoB and blood pressure are already being pushed by oral compounds than it does for the general population.

Side Effects & Risks

• Headache, the most common complaint and usually dose-related
• Nausea, heartburn, GI cramping
• Sweating, dizziness, low blood pressure at higher doses
• Flat or depressed mood at high cholinergic intakes, reported consistently enough to note
• Insomnia if taken late, though it is not a stimulant
• TMAO formation, of contested cardiovascular relevance
• No liver, kidney or hormonal burden at supplement doses

Blood Work & Monitoring

• No routine monitoring is required at ordinary doses
• Lipid profile (LDL, HDL, ApoB) — the panel that matters if it is taken at gram doses long-term, in line with the TMAO question
• Blood pressure — only relevant if dizziness or lightheadedness appears
• If the reason for taking it is subjective focus, sleep duration and caffeine timing move that variable considerably harder, and cost nothing